Alnylam Pharmaceuticals, Inc. (LON:0HD2)
435.57
-2.30 (-0.53%)
At close: Nov 7, 2025
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $1.25B USD in the quarter ending September 30, 2025, with 149.35% growth. This brings the company's revenue in the last twelve months to $3.21B, up 53.24% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.
Revenue (ttm)
$3.21B
Revenue Growth
+53.24%
P/S Ratio
18.60
Revenue / Employee
$1.44M
Employees
2,230
Market Cap
44.42B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
| Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
| Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
| Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
| Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Alnylam Pharmaceuticals News
- 16 hours ago - New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM - Business Wire
- 1 day ago - Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
- 2 days ago - What Does the Market Think About Alnylam Pharmaceuticals Inc? - Benzinga
- 4 days ago - American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors - Seeking Alpha
- 5 days ago - Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M - Seeking Alpha
- 5 days ago - Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Business Wire
- 5 days ago - Royalty Pharma (RPRX) Secures $310 Million Royalty Interest in Alnylam's AMVUTTRA - GuruFocus
- 5 days ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch